Trim 30-35% at upper Bollinger band ($1,183-$1,210) while preserving 65-70% core for structural compounding thesis
Underweight rating reflects stretched valuation (39.7x trailing P/E with 59% required forward EPS growth) in a hostile macro environment (10Y at 4.5%+, 96% no-cut probability, GLP-1 pricing reform). However, structural thesis remains intact given elite-tier fundamentals: 102% ROE, 54.2% operating margins (up from 45.1% YoY), $11B FCF inflection, 0.50 beta. Preserve 65-70% core to capture Q3 binary catalyst optionality (late October earnings, retatrutide Phase 3 readouts) while avoiding 8/28 anti-pattern of trimming defended secular compounder ahead of binary catalysts. Calibration against binding lessons: 9/21 reflection (alpha bleed on flat tape signals over-calibrated patience) warrants calibrated de-risking at upper band rather than passive hold. Upper Bollinger band is optimal trim zone because mean-reversion probability exceeds breakout probability (volume on 9/24 push to $1,197 was only 2.4M shares). Price target $1,260 implies 6-12 month strategic horizon. Sell triggers: close below $1,067, MFN executive order expansion to GLP-1s, Q3 volume deceleration >10%, forward EPS consensus below $42.
| Position | Action |
|---|---|
| Price at $1,183-$1,210 (upper Bollinger band zone) with neutral-bearish momentum (RSI 55.76 neutral, MACD -2.81) | Trim 30-35% of position; bias toward higher end (35-45% per Neutral Analyst guidance) |
| Close below $1,067 (200 SMA break) | Full exit of remaining 65-70% position — hard stop, no negotiating |
| Q3 2026 print shows revenue growth 48%+, stable Zepbound/Mounjaro, Foundayo traction reaffirmation | Upgrade to Hold |
| Q3 2026 print shows soft print or forward EPS cut >5% | Consider further 15-20% trim |
Eli Lilly is a generational healthcare compounder with 48% YoY revenue growth, best-in-class margins, and a manufacturing buildout signaling management conviction in multi-year GLP-1 demand; the stock is coiled for a technical breakout at $1,183 with valuation justified by accelerating earnings.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $1,162.44 | bullish |
| 50 SMA | $1,176.74 | neutral |
| 200 SMA | $1,067.50 | bullish |
| RSI (14) | 55.76 | neutral |
| MACD Line | -2.81 | bullish |
| MACD Signal | -8.59 | neutral |
| MACD Histogram | +5.78 | bullish |
| Bollinger Middle | $1,150.81 | neutral |
| Bollinger Upper | $1,190.39 | neutral |
| Bollinger Lower | $1,111.23 | neutral |
| ATR (14) | $32.48 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price at $1,067-$1,090 (200 SMA test)
Then: Reload one-third of trimmed position
The 40x trailing P/E is justified by accelerating earnings; forward EPS of $47.34 vs. TTM EPS of $29.78 implies ~59% earnings expansion, yielding a PEG ratio of 1.17
↩ rebuts: “The 33-40x P/E is too expensive”
EV: +70% (to $2,000 over 3-4 years per Langone); near-term targets of $1,292 and $1,400+ over 6-12 months · concedes: The 40x trailing P/E is historically elevated, though defended by 59% expected EPS growth and a PEG of 1.17; Novo Nordisk's $1.3B Nanexa deal and Viking's GLP-1 data represent legitimate future competition, though 2028+ earliest for new entrants; Rising 10-year yields at 2007 highs present headwinds, though LLY's earnings growth outpaces rate increases; The $90M Nektar lawsuit verdict exists as a legal liability, though immaterial relative to cash generation; Retail investor silence may reflect lack of awareness rather than contrarian opportunity
LLY at $1,183 is a fragile, hyper-concentrated, debt-fueled growth story trading at a multiple that punishes any disappointment—with concentrated revenue, rising debt, and increasing competitive and macro headwinds making the asymmetry to the downside greater than the upside.
EV: $1,067 (200-day SMA target); Reassess on pullback to $1,050-$1,100 · concedes: LLY is a phenomenal business with 54% operating margins and industry-leading cash generation; 48% revenue growth is real; Real franchise momentum in GLP-1s; 54% operating margin is real; Onswik approval is real; No single bull catalyst is necessarily wrong in isolation—it's the cumulative valuation risk that makes the setup dangerous
→ vs conservative: Hold 100% of position into Q3 October earnings exposes to binary outcome where a 5% earnings miss produces 15-25% drawdown given no multiple margin of safety at 39.7x trailing P/E
→ vs conservative: 162% D/E and $46B net debt leverage was acceptable during multiple expansion but amplifies drawdown asymmetrically if rates compress multiples or GLP-1 disappointments occur
→ vs neutral: Waiting for breakout above $1,190 or breakdown below $1,111 costs 6.7% round-trip in worse entry; signal will be priced in by time it triggers — you're buying yesterday's trade at tomorrow's price
→ vs neutral: RSI at 55.76 is neutral not bullish, MACD cross is earliest trigger not confirmation, 2.4M share volume on 9/24 at resistance ($1,197.79) signals test not conviction — mean reversion probability exceeds breakout probability
| neutral |
Support: 1176.74 · 1150.81 · 1111.23 | Resistance: 1190.39 · 1292.65
LLY remains in a mid-cycle consolidation within a durable long-term uptrend, with the 200 SMA ($1,067.50) providing a strong floor and the 50 SMA ($1,176.74) acting as the near-term pivot. The MACD histogram has turned positive (expanding from -8.59 signal), providing the earliest momentum buy trigger off the September bottom, while RSI at 55.76 offers room for further upside before overbought territory. Volatility has contracted with ATR at $32.48 and Bollinger Bands tightening, suggesting an imminent breakout is likely; a sustained close above $1,190.39 would target $1,230–$1,292, while a break below $1,111.23 would open a retest of the 50 SMA and potentially the 200 SMA vicinity.
Market Cap
$1.055 trillion
PE Ratio (TTM)
39.74
Forward PE
24.99
PEG Ratio
1.17
Price/Book
31.14
EPS (TTM)
$29.78
Forward EPS
$47.34
Dividend Yield
0.59%
Beta
0.502
52-Week High
$1,292.65
52-Week Low
$716.08
50-Day Avg
$1,177.13
200-Day Avg
$1,069.16
Q2 2026 Revenue
$22.97B
Q2 2026 Gross Profit
$19.71B
Q2 2026 Operating Income
$12.46B
Q2 2026 Net Income
$7.10B
Q2 2026 Diluted EPS
$7.94
TTM Revenue
$79.67B
TTM Net Income
$26.71B
Gross Margin (TTM)
83.4%
Operating Margin (TTM)
54.2%
Net Margin (TTM)
33.5%
ROE
102.3%
ROA
20.4%
EBITDA (TTM)
$41.7B
FCF (TTM)
$11.07B
Q2 2026 OCF
$10.69B
Q2 2026 CapEx
$2.93B
Q2 2026 FCF
$4.48B
Q2 2026 Acquisitions
$8.75B
Q2 2026 Debt Issued
$8.94B
Q2 2026 Buybacks
$1.60B
Q2 2026 Dividends
$1.55B
Total Assets
$142.28B
Total Liabilities
$108.40B
Stockholders' Equity
$33.88B
Total Debt
$54.91B
Cash & Equivalents
$8.95B
Net Debt
$45.96B
Current Ratio
1.355
Debt/Equity
162.1%
Working Capital
$16.93B
Goodwill & Intangibles
$26.96B
Net PPE
$29.29B
Revenue Growth (YoY Q2)
47.6%
Net Income Growth (YoY Q2)
25.4%
Strengths
Concerns
Eli Lilly posted Q2 2026 revenue of $22.97B (up 47.6% YoY) with industry-leading profitability metrics including 54.2% operating margin and 102.3% ROE, driven by its dominant GLP-1 franchise. The balance sheet expanded 41% YoY to $142.3B in total assets, funded by $8.94B in debt issuance to support $8.75B in acquisitions and heavy manufacturing capex of $2.93B in Q2 alone. While valuation is rich at Forward PE of 25x with ~59% expected EPS growth, the company's strong cash generation ($10.69B OCF in Q2) and strategic investments in capacity and pipeline position it well for continued execution, though concentration risk in GLP-1s and elevated leverage warrant monitoring.
Macro: Rising rate environment with 10Y Treasury at highest level since 2007 and 30Y at highest since 2004; mortgage rates creeping toward 7.5%; 96% probability of no Fed rate cuts in 2026 (up 1.1pp week-over-week); US recession odds at 10% by end-2026; Dow/S&P/Nasdaq all notched weekly gains despite bond rout; Trump-Xi meeting easing geopolitical risk premium